Greg Bell, Andrew Tepperman, and Justin Ho co-authored a chapter in the ninth edition of The Investment Treaty Arbitration Review. The chapter titled “Investment Treaty Disputes in the Life Sciences Industry” addresses the features and incentives of the life sciences industry as they lead to tensions and disputes between governments and companies. The chapter further discusses valuation considerations for practitioners and future issues arising from current developments in the life sciences industry.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.